0001404123-21-000009.txt : 20210607 0001404123-21-000009.hdr.sgml : 20210607 20210607073508 ACCESSION NUMBER: 0001404123-21-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210607 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210607 DATE AS OF CHANGE: 20210607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 1Life Healthcare Inc CENTRAL INDEX KEY: 0001404123 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 760707204 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39203 FILM NUMBER: 21998229 BUSINESS ADDRESS: STREET 1: ONE EMBARCADERO CENTER, SUITE 1900 CITY: San Francisco STATE: CA ZIP: 94111 BUSINESS PHONE: (415) 814-0927 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER, SUITE 1900 CITY: San Francisco STATE: CA ZIP: 94111 FORMER COMPANY: FORMER CONFORMED NAME: 1life Healthcare Inc DATE OF NAME CHANGE: 20070621 8-K 1 onem-20210607.htm 8-K onem-20210607
0001404123FALSE00014041232021-06-032021-06-0300014041232021-05-122021-05-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
__________________________  
FORM 8-K 
__________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2021
__________________________  
1LIFE HEALTHCARE, INC.
(Exact name of Registrant as Specified in Its Charter)
__________________________ 
 
 
Delaware001-3920376-0707204
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
One Embarcadero Center, Suite 1900
San Francisco, CA 94111
(415) 814-0927
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
__________________________  
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
Symbol(s)
 Name of each exchange
on which registered
Common Stock, $0.001 par value ONEM The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  



Item 7.01. Regulation FD Disclosure.

On June 7, 2021, 1Life Healthcare, Inc., a Delaware corporation (“One Medical”) and Iora Health, Inc., a Delaware corporation (“Iora”), issued a press release announcing the execution of an Agreement and Plan of Merger (the “Merger Agreement”) by and among One Medical, Iora, SB Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of One Medical, and Fortis Advisors LLC, solely in its capacity as the representative of the stockholders of Iora. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

A copy of the Merger Agreement will be filed with the Securities and Exchange Commission (the “SEC”) by amendment to this report as soon as reasonably practicable.

The information contained in this Item 7.01 and the accompanying Exhibit 99.1 are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall they be deemed incorporated by reference in any filing with the SEC made by One Medical, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Additional Information and Where to Find It

One Medical plans to file with the SEC, and the parties plan to furnish to the security holders of Iora and One Medical, a Registration Statement on Form S-4, which will constitute a prospectus and proxy statement of One Medical and will include an information statement of Iora, in connection with the proposed Merger, referred to as a proxy statement/prospectus, whereupon the separate corporate existence of Merger Sub shall cease and Iora shall continue as the surviving corporation of the Merger as a direct wholly owned subsidiary of One Medical. The proxy statement/prospectus described above will contain important information about One Medical, Iora, the proposed Merger and related matters. A proxy statement/prospectus will be sent to all One Medical stockholders. One Medical also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of One Medical are urged to read the registration statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Merger as they become available because they will contain important information about the proposed Merger.
Investors and security holders will be able to obtain free copies of these documents, and other documents filed with the SEC, by One Medical through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents from One Medical by contacting One Medical’s Investor Relations by email at investor@onemedical.com, or by going to the One Medical web page at https://investor.onemedical.com.

Participants in the Solicitation

The respective directors and executive officers of One Medical and Iora may be deemed to be participants in the solicitation of proxies from One Medical’s stockholders and written consents from the security holders of Iora in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the transaction described herein will be included in the proxy statement/prospectus described above.

No Offer or Solicitation

This Current Report on Form 8-K is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus that meets the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements

This Current Report on Form 8-K contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger. All statements contained in this Current Report on Form 8-K other than statements of historical facts are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, and you should not rely upon the forward-looking statements as predictions of future events. The future events and trends discussed in this Current Report on Form 8-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger, the ability of One Medical to timely and successfully achieve the anticipated benefits and potential synergies of the Merger and the impact of health epidemics, including the COVID-19 pandemic, on the parties’ respective



businesses and the actions the parties may take in response. Except to the extent required by law, One Medical does not undertake to update any of these forward-looking statements after the date of this Current Report on Form 8-K to conform these statements to actual results or revised expectations. A discussion of factors that may affect future results, including under the heading titled “Risk Factors”, is contained in One Medical’s SEC filings, including the most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which may be accessed at www.sec.gov. These documents can also be accessed on the One Medical web page at https://investor.onemedical.com.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 1LIFE HEALTHCARE, INC.
    
 By: /s/ Bjorn Thaler
Dated: June 7, 2021  Bjorn Thaler
   Chief Financial Officer


EX-99.1 2 snowbirdannouncementpressr.htm EX-99.1 Document

One Medical Announces Agreement to Acquire Iora Health
One Medical expands member-based, technology-powered primary care model to every stage of life, and extends into full-risk Medicare reimbursement models
Positions One Medical to deliver better health, better care, and lower costs across a combined 28 markets and beyond
SAN FRANCISCO – June 7, 2021 – 1Life Healthcare, Inc. (One Medical) (Nasdaq: ONEM), a leading human-centered and technology-powered primary care organization, today announced it has entered into a definitive agreement to acquire Iora Health, a human-centric, value-based primary care group with built-for-purpose technology focused on serving Medicare populations, in an all-stock transaction valued at approximately $2.1 billion.
“We are delighted to announce plans to combine with Iora Health, a technology-powered primary care leader delivering outstanding member-based, value-based care for adults 65+ enrolled in Medicare Advantage and other at-risk reimbursement models. Together we will expand our addressable market to serve more members in more geographies with digital and in-person care across every stage of life, with further capabilities to deliver care within full-risk models. Together with Iora Health, we can deliver better health, better care, and lower costs for children, adults, and seniors.” said Amir Dan Rubin, Chair & CEO of One Medical.

“Chris McKown and I founded Iora Health over 10 years ago to build an innovative primary care model that transforms lives and improves outcomes through relationship-based care, and we are excited to take this next exciting step with One Medical,” said Rushika Fernandopulle, M.D., MPP, Co-Founder and Chief Executive Officer of Iora Health. “Together, with our aligned cultures, shared mission, and complementary models, we can drive even greater impact for our patients, our teams, and our investors, and most importantly, our shared vision of transforming healthcare.”

One Medical and Iora Health are aligned in their missions, models, and cultures to transform healthcare for key stakeholders -- Consumers, Employers and Payers, Providers, and Health Networks. Together, the two companies can further accelerate and build upon their impacts for these stakeholders, while simultaneously expanding their models in existing markets, entering new markets, serving new populations, expanding full-risk models, and leveraging their purpose-built technologies for increased growth and scale
Strategic and financial benefits of the transaction include:
Creates a premier national member-based, technology-powered primary care platform to deliver better health, better care, and lower costs across Commercial and Medicare populations;
Positions One Medical with Iora Health to advance the health of members across every stage of life;
Extends One Medical’s platform to deliver multi-modal care with 24/7 national digital health and in-person care across a combined 28 markets and beyond;
Expands potential market opportunity to $870 billion across Commercial and Medicare segments, including the new Medicare Direct Contracting program;



Enhances One Medical’s risk-taking capabilities and extends One Medical into full-risk Medicare reimbursement models;
Amplifies the power of purpose-built technologies to deliver premier member experiences, population health, provider support, and value-based care across every stage of life;
Accelerates the expansion of two high-growth organizations, with complementary cultures and models serving as a premier place to practice modernized healthcare; and,

Offers an opportunity to create significant value, with an expected $350+ million in annual revenue synergies by 2025, ~$30 million in annual net cost synergies by 2025, and with ~$30 million in cumulative capex savings through 2025.
“One Medical has proven its ability to drive profitable membership growth, engage with members, improve health outcomes and lower costs. I am excited at the prospect of creating even more differentiation by adding Iora Health’s Medicare-focused capabilities, expanding our reach to 28 markets, and offering our service experience to the parents and grandparents of our 598 thousand members,” said Bjorn Thaler, Chief Financial Officer, One Medical.
Leadership and Governance
A designee of Iora Health will join the One Medical Board and Rushika Fernandopulle will become One Medical’s Chief Innovation Officer.
Transaction Details
Under the terms of the agreement, Iora Health shareholders will receive 56.1 million shares of One Medical common stock. Based on the closing share price of One Medical’s common stock of $35.59 on June 4th, 2021, the total transaction is valued at approximately $2.1 billion. Upon completion of the transaction, Iora Health shareholders are expected to own approximately 26.75% of the combined company.
The transaction is expected to close in late Q3 or Q4 of 2021 and is subject to customary closing conditions, including approval by One Medical and Iora Health stockholders and receipt of regulatory approval.
Advisors
Morgan Stanley & Co. LLC served as exclusive financial advisor to One Medical and Cooley LLP served as legal advisor.
Credit Suisse served as exclusive financial advisor to Iora Health and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor.
Conference Call Details



One Medical will host a conference call at 5:00 a.m. (PT) / 8:00 a.m. (ET) on Monday, June 7, 2021, to discuss this transaction. A live audio webcast and a supplemental presentation will be available online at https://investor.onemedical.com. The conference call can also be accessed by dialing 1-800-258-1651 for U.S. participants, or 1-612-979-9928 for international participants, and referencing conference ID 2077477. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
Available Information
Additional information is available at https://onemedical.com/announcing-iora. One Medical intends to use its Company website (including its Investor Relations website) as well as its Facebook, Twitter and LinkedIn accounts as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Additional Information and Where to Find It
One Medical plans to file with the SEC, and the parties plan to furnish to the security holders of Iora Health and One Medical, a Registration Statement on Form S-4, which will constitute a prospectus and proxy statement of One Medical and will include an information statement of Iora Health, in connection with the proposed Merger, referred to as a proxy statement/prospectus, whereupon the separate corporate existence of Merger Sub shall cease and Iora Health shall continue as the surviving corporation of the Merger as a direct wholly owned subsidiary of One Medical. The proxy statement/prospectus described above will contain important information about One Medical, Iora Health, the proposed Merger and related matters. A proxy statement/prospectus will be sent to all One Medical stockholders. One Medical also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of One Medical are urged to read the registration statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Merger as they become available because they will contain important information about the proposed Merger.
Investors and security holders will be able to obtain free copies of these documents, and other documents filed with the SEC, by One Medical through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents from One Medical by contacting One Medical’s Investor Relations by email at investor@onemedical.com, or by going to the One Medical web page at https://investor.onemedical.com and clicking on the links titled “Financial Information” and “Investor Services.”
Participants in the Solicitation
The respective directors and executive officers of One Medical and Iora Health may be deemed to be participants in the solicitation of proxies from One Medical’s stockholders and written consents from the security holders of Iora Health in connection with the proposed Merger. Information regarding the interests of these directors and executive officers in the transaction described herein will be included in the proxy.



Forward-Looking Statements
This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger. All statements contained in this press release other than statements of historical facts, including business strategy and plans and objectives for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “can”, “may,” “assume,” “project,” “will,” “plan,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, and you should not rely upon the forward-looking statements as predictions of future events. The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger, the ability of One Medical to timely and successfully achieve the anticipated benefits and potential synergies of the Merger and the impact of health epidemics, including the COVID-19 pandemic, on the parties’ respective businesses and the actions the parties may take in response thereto; the strength of the One Medical brand; member satisfaction with our services and support; anticipated membership growth and revenue potential from our members; our ability to retain members; our ability to successfully introduce and drive adoption of new products; changes in the pricing we offer our members; our relationships with our health network partners and enterprise clients and any changes to, accommodations in or terminations of our contracts with the health network partners or enterprise clients; our ability to improve cost of care and margins, including timing and expenses of new office openings and entry into new geographic markets; changes in laws or regulations; our involvement in litigation, including medical malpractice claims and consumer class actions; any governmental investigations or inquiries into our business and operations or challenges to our relationships with the One Medical PCs under the administrative services agreements; our strategic plan; our financial outlook; our focus areas for investment and our investments; announcements by us or our competitors of business or strategic developments; and our overall business trajectory. Except to the extent required by law, One Medical does not undertake to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations. A discussion of factors that may affect future results, including under the heading titled “Risk Factors”, is contained in One Medical’s SEC filings, including the most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which may be accessed at www.sec.gov.
This press release may include certain non-GAAP financial measures as defined by SEC rules. Because not all companies calculate non-GAAP financial information identically (or at all), the presentations herein may not be comparable to other similarly titled measures used by other companies. Further, such non-GAAP financial information should be considered in addition to, and not as superior to or as a substitute for, the historical consolidated financial statements prepared in accordance with GAAP.
About One Medical



One Medical is a membership-based and technology-powered primary care platform with seamless digital health and inviting in-office care, convenient to where people work, shop, live, and click. Our vision is to delight millions of members with better health and better care while reducing costs. Our mission is to transform health care for all through our human-centered, technology-powered model.
Headquartered in San Francisco, 1Life Healthcare, Inc. is the administrative and managerial services company for the affiliated One Medical physician-owned professional corporations that deliver medical services in-office and virtually. 1Life and the One Medical entities do business under the “One Medical” brand.
About Iora Health
Iora Health is building a different kind of health system to deliver high impact relationship-based care. With a mission to restore humanity to health care and a goal to transform healthcare overall, Iora Health’s care model provides extraordinary service to patients to ensure improved health outcomes while lowering overall health costs. Our patients enjoy the benefits of better access to care, office- and non-office-based encounters (e.g. phone, text messages, and email), an accessible and transparent medical record, and robust educational offerings. Our practices across the U.S. enjoy the benefits of smaller panel sizes, closer relationships with patients, and the opportunity to lead systemic change in health care delivery while working with a true team.
One Medical Investor Contact:
Rose Salzwedel, One Medical
Director of Investor Relations
investor@onemedical.com
206-331-2211

One Medical Media Contact:
Kristina Skinner, One Medical
Senior Director of External Communications
press@onemedical.com
650-743-5187

Iora Health Media Contact:
Kathleen Haley, Iora Health
Vice President of Communications & Patient Experience
kathleen.haley@iorahealth.com
617-545-5284


EX-101.SCH 3 onem-20210607.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 onem-20210607_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Ex Transition Period Entity Ex Transition Period Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 onem-20210607_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 onem-20210607_htm.xml IDEA: XBRL DOCUMENT 0001404123 2021-06-03 2021-06-03 0001404123 2021-05-12 2021-05-12 0001404123 false 8-K 2021-06-07 1LIFE HEALTHCARE, INC. DE 001-39203 76-0707204 One Embarcadero Center Suite 1900 San Francisco CA 94111 (415) 814-0927 true false false false Common Stock, $0.001 par value ONEM NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
Jun. 03, 2021
May 12, 2021
Cover [Abstract]    
Document Type 8-K  
Document Period End Date Jun. 07, 2021  
Entity Registrant Name 1LIFE HEALTHCARE, INC.  
Entity Central Index Key   0001404123
Amendment Flag   false
Entity Incorporation, State or Country Code DE  
Entity File Number 001-39203  
Entity Tax Identification Number 76-0707204  
Entity Address, Address Line One One Embarcadero Center  
Entity Address, Address Line Two Suite 1900  
Entity Address, City or Town San Francisco  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94111  
City Area Code (415)  
Local Phone Number 814-0927  
Written Communications true  
Soliciting Material false  
Pre-commencement Tender Offer false  
Pre-commencement Issuer Tender Offer false  
Title of 12(b) Security Common Stock, $0.001 par value  
Trading Symbol ONEM  
Security Exchange Name NASDAQ  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 2 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.onemedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports onem-20210607.htm onem-20210607.xsd onem-20210607_lab.xml onem-20210607_pre.xml snowbirdannouncementpressr.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "onem-20210607.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 2, "dts": { "inline": { "local": [ "onem-20210607.htm" ] }, "labelLink": { "local": [ "onem-20210607_lab.xml" ] }, "presentationLink": { "local": [ "onem-20210607_pre.xml" ] }, "schema": { "local": [ "onem-20210607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "onem", "nsuri": "http://www.onemedical.com/20210607", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "onem-20210607.htm", "contextRef": "ib1ef3a0dc89f4933b08cae4c1b31ef80_D20210603-20210603", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.onemedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "onem-20210607.htm", "contextRef": "ib1ef3a0dc89f4933b08cae4c1b31ef80_D20210603-20210603", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.onemedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001404123-21-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001404123-21-000009-xbrl.zip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

VXNSJ:FB176+TUV%^\&JZFU-L [J_2G?SN%^VA6#NRAMT)LY)U'S:<5+XS M\&BB[Y/>]AC0J[WKD/#^[KR@V3*M2B>K==<

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